The company's team of researchers, in partnership with universities and other pharmaceutical companies, specializes in creating DNA-based drugs that target specific mutated genes causing diseases, with a focus on pediatric cancer. Their platform, MyGenera, enables them to quickly identify and develop new drugs for each specific therapeutic target, resulting in faster treatment and higher success rates for patients.